Quotient (NASDAQ:QTNT) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday, October 2nd.
Separately, ValuEngine upgraded shares of Quotient from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Quotient presently has a consensus rating of “Hold” and a consensus target price of $11.50.
QTNT opened at $6.41 on Tuesday. The company has a debt-to-equity ratio of -3.11, a quick ratio of 1.59 and a current ratio of 2.11. Quotient has a 1-year low of $2.78 and a 1-year high of $9.02. The firm has a market cap of $408.63 million, a price-to-earnings ratio of -3.17 and a beta of 0.17.
A number of institutional investors and hedge funds have recently bought and sold shares of QTNT. Trexquant Investment LP bought a new position in Quotient during the second quarter valued at about $102,000. The Manufacturers Life Insurance Company boosted its position in Quotient by 341.8% during the first quarter. The Manufacturers Life Insurance Company now owns 21,820 shares of the company’s stock worth $103,000 after purchasing an additional 16,881 shares during the period. West Chester Capital Advisors Inc. bought a new position in Quotient during the second quarter worth about $120,000. Bank of America Corp DE boosted its position in Quotient by 539.0% during the second quarter. Bank of America Corp DE now owns 16,768 shares of the company’s stock worth $135,000 after purchasing an additional 14,144 shares during the period. Finally, Opaleye Management Inc. bought a new position in Quotient during the first quarter worth about $282,000. Institutional investors own 49.25% of the company’s stock.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Recommended Story: Book Value Per Share in Stock Trading
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.